Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
08 sept. 2023 04h00 HE
|
Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
Jupiter Wellness Reports Positive Efficacy Results from Clinical Study for its NoStingz Topical Jellyfish Protection Sunscreen
09 août 2023 08h45 HE
|
Jupiter Wellness, Inc
Data show NoStingz proprietary formulation provides protection against jellyfish stings including Portuguese man-o’-war JUPITER, FL, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Jupiter Wellness, Inc....
Groundbreaking Study in Nature Digital Medicine Establishes Sword Health’s Digital Physical Therapy Program as the New Gold Standard of Care for the 50 Million Americans Who Endure Physical Pain Daily
10 juil. 2023 09h00 HE
|
SWORD Health
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Today, Sword Health, the world’s first end-to-end platform to predict, prevent and treat pain, is announcing its digital physical therapy program has been...
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
06 juil. 2023 06h30 HE
|
Revive Therapeutics Ltd.
TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
28 juin 2023 04h00 HE
|
AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
28 juin 2023 04h00 HE
|
AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
28 juin 2023 04h00 HE
|
AKAMPION
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
30 mai 2023 07h30 HE
|
Revive Therapeutics Ltd.
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
22 mai 2023 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
18 mai 2023 13h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...